 "Divi’s Labs: APIs, custom synthesis, ongoing capex plan to support growth")
The Divi’s Laboratories stock gained 44 per cent over the past month after a record June quarter (Q1) performance and expectations that revenue growth outperformance will continue. In addition to structural tailwinds in active pharmaceutical ingredients (APIs), its relationships with global pharma majors, ongoing capex programme, and strong execution are expected to support growth prospects.
Its recent gains, however, have been on account of its Q1 performance, which was its best ever. Led by broad-based growth across its three segments of APIs, custom synthesis, and carotenoids, the firm posted a 49 per cent growth in revenues and 78 per cent uptick
